Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan's Botox Holds Its Own In Migraine, Despite CGRP Competition

Oct 31 2018

• By Emily Hayes

Businessman comparing two documents, neutral background

Related Content

No Fire Sale: Allergan May Sell Women’s Health, Infectious Disease Units

May 30 2018

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Apr 28 2018

Allergan Buys Bonti, Releases New Data In Defense Of 'Iconic' Botox Brand

Sep 15 2018

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

Sep 18 2018

Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio

Aug 03 2018

Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD

Jul 20 2018

Allergan Fights Generic Headwinds, Activist Investors

Jul 26 2018

Related Companies

Allergan plc

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Bonti, Inc.

Molecular Partners AG

Genentech, Inc.

Almirall SA

Additional Topics

Sales & Earnings Business Strategies Commercial Neurology BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window